Link to Full Article Initial clinical emphasis on difficult-to-treat respiratory infections in cystic fibrosis patients MARINA DEL REY, Calif., Sept. 12, 2019 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (the “Company” or “Armata”), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that the Company has developed a new synthetic phage […]

Link to Full Article Patent allowances cover various aspects of the Company’s phage program and lead product candidate, AP-SA01 Company to host bacteriophage Key Opinion Leader meeting and live webcast on Wednesday, June 26 MARINA DEL REY, Calif., June 3, 2019 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a clinical-stage biotechnology company focused on precisely targeted bacteriophage […]

Link to Article Shares of the combined company to commence trading on the NYSE American exchange under the new symbol “ARMP” on May 10, 2019 Completed $10 million concurrent financing Ongoing collaboration with Merck to develop proprietary synthetic phage candidates MARINA DEL REY, Calif., May 9, 2019 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata”), a clinical-stage […]

Link to full article Entered into a merger agreement with C3J Therapeutics that is expected to result in an NYSE American-listed company focused on development of precisely-targeted bacteriophage therapeutics  $10.0 million of new capital will be invested in combined company to be re-named Armata Pharmaceuticals  Preliminary Merger proxy filed with the SEC on March 25, […]

AmpliPhi’s wholly owned GMP facility now capable of producing material for over 100,000 doses from each drug substance batch of AB-SA01, sufficient to support clinical trial requirements CATEGORY: Featured Tuesday, December 18, 2018 6:50 am EST SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEAM: APHB “The improved manufacturing productivity that we have achieved for AB-SA01 is […]